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Abstract
The intervertebral disc is an important mechanical 
structure that allows range of motion of the spinal column. 
Degeneration of the intervertebral disc – incited by aging, 
traumatic insult, genetic predisposition, or other factors 
– is often defined by functional and structural changes 
in the tissue, including excessive breakdown of the 
extracellular matrix, increased disc cell senescence and 
death, as well as compromised biomechanical function 
of the tissue. Intervertebral disc degeneration is strongly 
correlated with low back pain, which is a highly prevalent 
and costly condition, significantly contributing to loss in 
productivity and health care costs. Disc degeneration is 
a chronic, progressive condition, and current therapies 
are limited and often focused on symptomatic pain relief 
rather than curtailing the progression of the disease. 
Inflammatory processes exacerbated by cytokines tumour 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are 
believed to be key mediators of disc degeneration and low 
back pain. In this review, we describe the contributions of 
TNF-α and IL-1β to changes seen during disc degeneration 
at both cellular and tissue level, as well as new evidence 
suggesting a link between infection of the spine and low 
back pain, and the emerging therapeutic modalities aimed 
at combating these processes.
Keywords: Intervertebral disc, nucleus pulposus, 
cytokines, extracellular matrix, tumour necrosis factor, 
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Introduction
The intervertebral disc (IVD) comprises an outer 
circumferential annulus fibrosus (AF) and an inner cell-
sparse, matrix-rich nucleus pulposus (NP), bordered 
superiorly and inferiorly by two cartilaginous endplates. 
The AF is a lamellar fibrocartilaginous structure rich in 
collagen I, derived from embryonic sclerotome, and is 
responsible for withstanding large hoop stress from the 
pressurised NP, and tensile and torsional stresses from 
motion of adjacent vertebrae (Guterl et al., 2013). The NP 
encompasses a physiologically hypoxic and hyperosmotic 
niche; cells residing within the NP are derived from the 
embryonic notochord (Risbud et al., 2010; Risbud and 
Shapiro, 2011; Johnson et al., 2014; Choi et al., 2015). 
NP cells are phenotypically defined in part by the distinct 
ratio of synthesised aggrecan and collagen II (Mwale et 
al., 2004; Risbud et al., 2015). The hydrated, aggrecan-rich 
extracellular matrix (ECM) resists large compressive loads 
from the trunk, allowing us to remain upright (Vergroesen 
et al., 2015). Degeneration of the NP, AF and IVD as 
a structure is often defined by functional and structural 
changes in the tissue, including excessive breakdown 
of ECM by proteases and increased cell senescence and 
death (Roughley, 2004; Adams and Roughley, 2006). IVD 
degeneration is strongly correlated with low back pain 
(LBP) (Chou et al., 2011; Livshits et al., 2011), which is 
a highly prevalent, costly, and crippling condition across 
the globe (Katz, 2006; Hoy et al., 2012). Inflammatory 
processes, exacerbated by cytokines tumour necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) are believed to 
be key events during disc degeneration and associated LBP 
(Risbud and Shapiro, 2014). In this review, we describe the 
specific contributions of TNF-α and IL-1β to cellular and 
tissue level changes seen during disc degeneration, discuss 
new evidence suggesting a link between infection of the 
spine and LBP, and the emerging therapeutic modalities 
aimed at combating these processes. Specifically, the 
effects of cytokines on breakdown of disc ECM and 
potential activation of Toll-like receptors, the immune 
response, disc cell homeostasis, and resolution of disc 
herniation are discussed, as well as potential triggering 
mechanisms for this cytokine activity.
Initiating events that may contribute to elevated 
cytokine production by disc cells and spinal tissues
It has been well established that inflammatory changes in 
the disc contribute to degeneration, and that trauma and 
genetic predisposition may contribute to some aspects of 
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this cascade. However, the question remains of the initiating 
event(s) that promotes production of these cytokines by 
NP and AF cells, especially in the absence of acute trauma 
or herniation. One possible initiator is chronic overload 
of the disc, which has been shown to cause degenerative 
changes in several models (Adams et al., 2000). Discs from 
rats subjected to in vivo dynamic compression overloading 
over 8 weeks showed increased matrix metalloproteinase 
(MMP)-associated aggrecan degradation products in both 
the AF and NP compared to sham discs (Iatridis et al., 
2011). Some evidence exists, correlating bacterial infection 
with degenerative disc disease and LBP. In one study, 
53 % of surgical microdiscectomy samples from patients 
with sciatica were positive for bacterial cultures (Stirling 
et al., 2001). In another recent study, herniated nuclear 
tissue removed during surgery was positive for microbial 
cultures in 46 % of patients, and significantly correlated 
with Modic changes in adjacent vertebral endplates, which 
are highly associated with LBP (Jensen et al., 2008; Albert 
et al., 2013a). Additional studies have also shown evidence 
of bacterial infection in some painful degenerate discs, 
even in the absence of overt clinical infection (Stirling et 
al., 2002; Fritzell et al., 2004; Agarwal et al., 2011; Arndt 
et al., 2012).
 In 2008, Albert et al. (2008a) proposed the hypothesis 
that some cases of degenerative disc disease and low back 
pain have an infectious cause, supported by a pilot study 
investigating the efficacy of antibiotics for the treatment 
of patients with persistent LBP and Modic changes that 
did not respond to initial conservative therapy (Albert et 
al., 2008b). In this pilot study, there was a statistically and 
clinically significant improvement in patients receiving 
a course of amoxicillin-clavulanate antibiotics. A larger 
double-blind randomised clinical trial followed and 
similarly reported significant improvement in disability 
and pain in patients treated with antibiotics compared to 
placebo (Albert et al., 2013b). Importantly, some evidence 
suggests that clavulanate has anti-inflammatory and 
analgesic properties, which may confound interpretation 
of clinical findings by Albert et al. (Casellas et al., 
1998; Hajhashemi and Dehdashti, 2014). In addition, 
some investigators have suggested that the presence of 
bacteria in disc samples arises from contamination of skin 
commensals (e.g. Proprionibacterium acnes) during non-
sterile surgical and collection procedures (McLorinan et 
al., 2005; Ben-Galim et al., 2006; Carricajo et al., 2007; 
Wedderkopp et al., 2009); it may also arise from infected 
endplate and bony avulsions (Rajasekaran et al., 2013). 
In spite of the controversial nature, subclinical bacterial 
infection of endplate/vertebrae and/or discitis as a cause for 
disc degeneration and LBP warrants further consideration 
and careful investigation.
 Bacterial infection of the disc may initiate inflammatory 
cascades through activation of components of the innate 
immune response. Toll-like receptors (TLRs) are plasma- 
and endolysosomal-bound pattern recognition receptors, 
best characterised as expressed on the surface of cells of 
the immune system (De Nardo, 2015). TLRs recognise 
pathogen-associated molecular patterns (PAMPs), and 
activate inflammatory signalling cascades (Kumar et al., 
2009). Most relevant to bacterial infection are TLR2 and 
TLR4. TLR2 recognises a range of PAMPs including 
peptidoglycans expressed in the cell wall of Gram-positive 
bacteria (Zähringer et al., 2008), while TLR4 is activated 
by lipopolysaccharide (LPS) in the cell wall of Gram-
negative bacteria (Poltorak et al., 1998). Activation both 
TLR2 and TLR4 signalling results in transcription of many 
pro-inflammatory cytokines through the MyD88 pathway 
(Kawai et al., 1999).
 Interestingly, NP cells also express TLRs with a recent 
study identifying expression of TLR1/2/3/4/5/6/9/10 in 
isolated human IVD cells. Importantly, expression levels 
of TLR2 and TLR4 were raised with increasing grade 
of degeneration (Klawitter et al., 2014). Another study 
showed that treatment of IVD cells with LPS resulted 
in increased expression of TNF-α, IL-1β, and IL-6, 
and decreased expression of aggrecan and collagen II. 
Furthermore, injection of LPS into discs in vivo induced 
degenerative changes (Rajan et al., 2012). Ellman et al. 
(2012) demonstrated that inhibition of MyD88 attenuated 
the changes in catabolic gene expression incurred by LPS 
in vitro as well as in an ex vivo organ culture model. These 
studies suggest that not only can innate immunity initiate 
degenerative changes in the disc, but it can also perpetuate 
inflammatory cascades and promote progressive disease.
The TNF and IL-1 signalling pathways
TNF-α is synthesised by cells as a 26 kDa type II 
transmembrane protein termed mTNF. This membrane-
bound form is processed to a 17 kDa soluble form, 
sTNF, by the metalloproteinase tumour necrosis factor-
α-converting enzyme (TACE) also known as ADAM 
metallopeptidase domain 17 (ADAM17). The trimeric 
forms of both mTNF and sTNF are biologically active, 
although monomeric and dimeric forms also exist (Black 
et al., 1997). TNF-α interacts with either of two receptors 
of the tumour necrosis factor receptor (TNFR) superfamily, 
TNFR1 or TNFR2. mTNF can bind either receptor, 
while sTNF can bind TNFR1 only. TNFR1 activation by 
TNF-α leads to formation of two distinct TNF signalling 
complexes: Complex 1 has anti-apoptotic functions, 
while Complex II/death inducing signalling complex 
(DISC) induces apoptosis after receptor internalisation. 
TNFR2, on the other hand, lacks an intracellular death 
domain. Therefore, signalling through this complex is 
considered anti-apoptotic. Recent evidence, however, 
suggests that TNFR2 may induce degradation of TNF 
receptor-associated factor 2 (TRAF2), resulting in crosstalk 
between the TNFR1 and TNFR2 pathways. Signalling 
through Complex I activates the nuclear factor κB (NF-κB) 
and mitogen activated protein kinase (MAPK) pathways 
(Cabal-Hierro and Lazo, 2012) (See Fig. 1). Relevant to 
this review, high levels of TNF-α have been associated with 
disc degeneration (discussed in the following sections).
 IL-1α and IL-1β, members of the IL-1 family of 11 
cytokines, are first synthesised as precursor proteins and 
then activated through intracellular proteolytic cleavage by 
calpain and caspase-1, respectively. Secreted pro-IL-1β can 
also be activated extracellularly by neutrophil proteases. 
While pro-IL-1β requires this activation, membrane-bound 
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Fig. 1. TNF-α signalling pathway. Membrane-bound TNF (mTNF) is processed by the metalloproteinase TACE/
ADAM-17 to the soluble form (sTNF). sTNF-α or mTNF-α may bind the transmembrane TNFR1 receptor, causing a 
conformational change that releases the inhibitory SODD protein. Binding results in the recruitment of several factors 
including TRADD, RIP1, TRAF2 and cIAP 1 and 2, resulting in formation of Complex I that signals through either 
the NF-κB or MAPK pathways to activate p65 or AP1, respectively. Complex I signalling results in transcription of 
inflammatory (chemokines, cytokines) and matrix catabolic genes (MMPs, ADAMTSs) as well as pro-survival genes 
(cIAP1 and 2, cFLIP, TRAF1, TRAF2). Alternatively, mTNF-α may activate the TNFR2 receptor to form a similar 
complex and downstream signalling cascade. In some instances, TNFR1 bound to sTNF-α may be internalised, initiating 
Complex II or DISC formation that leads to cleavage of procaspase 8 and finally cell apoptosis. Abbreviations: TNF-α, 
tumour necrosis factor α; TACE, TNF-α converting enzyme; ADAM-17, a disintegrin and metalloproteinase domain 
containing protein 17; TNFR1, TNF receptor 1; SODD, silencer of death domains; TNFR2, TNF receptor 2; TRADD, 
TNFR1-assoicated death domain protein; RIP1, receptor-interacting protein 1; TRAF2, TNF-receptor-associated 
factor 2; cIAP, baculoviral IAP repeat containing; DISC, death-inducing signalling complex; NF-κB, nuclear factor 
κB; MAPK, mitogen-activated protein kinase; DD, death domain.
pro-IL-1α can signal through interleukin 1 receptor type 
I (IL-1R1) on adjacent cells without proteolytic cleavage. 
In addition, the 16 kDa N-terminal propeptide cleavage 
product of pro-IL-1α (ppIL-1α) can translocate into the 
nucleus and is thought to function as a transcriptional 
modulator. Both IL-1α and IL-1β through binding IL-1R1, 
can stimulate NF-κB, JNK, and p38 MAPK signalling 
pathways, resulting in phosphorylation of various proteins 
involved in transcription of inflammatory and catabolic 
genes such as IL-6, IL-8, MCP-1, COX-2, IκBα, IL-1α, 
IL-1β and MKP-1 (Gabay et al., 2010; Weber et al., 2010).
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TNF and IL-1 are closely associated with 
intervertebral disc degeneration
Associations between herniation, disc degeneration, and 
the inflammatory response have been well established. 
Herniated disc tissue exhibits a large inflammatory cell 
response with macrophages being predominant players 
and increased TNF-α, IL-1β and many other cytokines 
detected at the site of herniation (Grönblad et al., 1994; 
Takahashi et al., 1996). A 2012 study of NP samples 
from adolescent patients found an increased number of 
TNF-α-immunoreactive cells in painful herniated samples 
compared to non-painful scoliotic controls (Ohtori et al., 
2012a). Importantly, during disc degeneration TNF-α and 
IL-1β are not only produced by leukocytes, but also by IVD 
cells themselves (Le Maitre et al., 2005; Le Maitre et al., 
2007b). In addition, TNFR1, TNFR2, TACE, interleukin-1 
receptor antagonist (IL-1ra) and IL-1R1 are expressed in 
human nucleus pulposus tissue, and expression of TNF-α 
and IL-1β increases with age and severity of degeneration 
in both humans and animal models (Oda et al., 2004; Le 
Maitre et al., 2005; Bachmeier et al., 2007; Le Maitre 
et al., 2007b; Wang et al., 2013b). Furthermore, another 
study confirmed expression of both TNFR1 and TNFR2 
in NP tissue from patients with disc herniation, with levels 
of TNFR1 being positively correlated with degree of 
pain (Andrade et al., 2011). In addition, IL-1 gene family 
polymorphisms, IL-1RN G1812A, IL-1α C889T, and 
IL-1β C3954T, are associated with increased risk of LBP 
(Solovieva et al., 2004). Importantly, expression of these 
cytokines is not merely correlated with degeneration, but 
is believed to be causative of disease.
TNF and IL-1 contribute to disc disease through 
degradation of ECM
One meaningful characteristic of disc degeneration is 
disruption of the ECM. TNF-α and IL-1β have been 
shown in many contexts to induce degenerative changes 
to the ECM. Induction of catabolic enzymes a disintegrin 
and metalloproteinase with thrombospondin motifs 
(ADAMTS)-4 and -5, and matrix metalloproteinases 
(MMPs) -1, -2, -3, -4, -13 and -14, and concurrent decrease 
in expression of anabolic ECM proteins aggrecan and 
collagen II is mediated by both IL-1β and TNF-α (Doita 
et al., 2001; Shen et al., 2003; Jimbo et al., 2005; Le 
Maitre et al., 2005; Séguin et al., 2005; Murata et al., 
2006; Le Maitre et al., 2007a; Bachmeier et al., 2009; 
Pockert et al., 2009; Wang et al., 2011; Wang et al., 
2014a). Séguin et al. (2008) showed that TNF-α-induced 
increase in MMP2 activity was specifically associated 
with upregulation of membrane type MT1-MMP. A 
recent study by Ye et al. (2015) showed that unlike in 
chondrocytes, NP cell expression of xylosyltransferase-1 
(XT-1), a key enzyme in glycosaminoglycan synthesis, is 
unaffected by TNF-α and IL-1β treatment, suggesting that 
the effects of these cytokines on the ECM homeostasis 
are fairly cell-type-specific. Further studies have shown 
that TNF-mediated activation of ADAMTS4 occurs 
through ERK1, p38 and NF-κB pathways in NP cells 
(Tian et al., 2013). In organ culture models, treatment 
with TNF-α resulted in suppression of multiple collagen 
types, aggrecan, fibromodulin, increased expression of 
MMPs and pain-associated molecule nerve growth factor 
(NGF) (Ponnappan et al., 2011), and compromised disc 
biomechanics (Walter et al., 2015a). These results contrast 
with that of Hoyland et al. (2008), which showed that 
TNF-α treatment had little effect on matrix degradation 
as assessed by in situ zymography on gelatin, collagen II, 
and casein, although changes were seen after treatment 
with IL-1β. This differential response may be explained by 
differences in concentration, duration of TNF-α treatment, 
culture system, and/or species between the studies. Not 
surprisingly, the relative importance of each of these 
inflammatory mediators is still debated. Nonetheless, 
both of these cytokines have been shown under numerous 
conditions to control catabolic gene expression in disc 
tissues.
 TNF-α and IL-1β also suppress expression of 
matricellular protein connective tissue growth factor 
(CCN2/CTGF), an important regulator of cellular adhesion, 
proliferation, migration and ECM synthesis (Tran et al., 
2010; Tran et al., 2014). Tran et al. (2014) demonstrated 
that the activity of these cytokines on CCN2 expression 
was NF-κB-dependent. In addition, CCN2 successfully 
suppressed IL-1β mediated induction of catabolic 
molecules MMP-3, ADAMTS5, syndecan-4 and prolyl 
hydroxylase 3 (PHD3), and this inhibition was through 
αvβ3 and α5β1 integrins, indicating a protective role of 
CCN2 in pathogenesis of disc disease.
 Many of the effects of TNF-α and IL-1β on the ECM 
are mediated through the NF-κB signalling pathway and 
the heparan-sulphate proteoglycan syndecan-4. Fujita et 
al. (2012) showed that prolyl hydroxylase 3 (PHD3) acts 
as a coactivator of p65 to propagate matrix catabolism 
induced by TNF-α. TNF-α treatment of NP cells induces 
expression of PHD3, which then interacts with p65 to 
promote transcription of syndecan-4, ADAMTS5, MMP-
13 and COX2. More recent work has confirmed that PHD2 
plays a similar role in the NP in promoting p65-mediated 
transcription (Li et al., 2015). Syndecan-4 is required 
for TNF-α and IL-1β-dependent increase in expression 
and activity of ADAMTS5 and MMP-3 in rat NP cells 
(Wang et al., 2011; Wang et al., 2014a). Adding another 
dimension to cytokine action on disc cells, Ye et al. (2011) 
demonstrated a positive relationship between TNF-α and 
Wnt/β-catenin signalling in NP cells and showed that 
TNF-α activates the Wnt/β-catenin pathway, thereby 
increasing expression of MMP-13. Additionally, Wnt 
signalling induces TNF-α expression in NP cells, possibly 
leading to a pro-degenerative feed-forward loop between 
the two signalling pathways (Hiyama et al., 2013).
 In vivo studies support the role of these endogenous 
cytokines in the degenerative process of the IVD. Mice 
lacking functional IL-1ra, an endogenous antagonist for 
IL-1R1, demonstrated loss of proteoglycans and increased 
expression of MMP-3, -7 and ADAMTS4 in their IVDs. 
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Compared to wild type mice, discs of IL-1ra-/- mice had 
higher histological grade of degeneration, and disc cells 
exhibited diminished proliferative capacity (Phillips et al., 
2013). Similarly, Kang et al. (2015) showed that injection 
of TNF-α in a porcine model was sufficient to induce 
early-stage disc degeneration, characterised by matrix loss, 
annular fissure formation, and vascularisation.
Activation of TLRs by endogenous matrix ligands 
may exacerbate the disease progression through 
cytokine production
Additionally, matrix catabolism products may contribute 
to progression of disc disease by serving as endogenous 
ligands of TLRs and, thus, exacerbating the inflammatory 
state. Biglycan is a small, leucine-rich proteoglycan 
expressed in the IVD. Proteolytically-cleaved biglycan has 
been shown to activate proinflammatory cascades through 
binding to TLR2 and TLR4 in macrophages (Schaefer 
et al., 2005). Relevant to this discussion, biglycan has 
been shown to be extensively fragmented in pathological 
human IVDs (Brown et al., 2012). Similarly, fibronectin 
fragments (Fn-f) can act as endogenous ligands for TLR4 
(Okamura et al., 2001), fibronectin fragmentation increases 
in degenerated discs possibly due to increased ADAM8-
mediated cleavage (Ruel et al., 2014), and injection 
of 30 kDa N-terminal Fn-f in rabbit discs promotes 
degeneration (Anderson et al., 2005). Similarly, versican, a 
large aggregating proteoglycan that is expressed in the disc 
(Sivan et al., 2014), is shown to activate TLR2 and TLR6 
(Kim et al., 2009). While the in vivo evidence is limited, 
there are indeed studies showing activation of TLR by 
ECM components in NP, giving credence to the hypothesis. 
Fragments of hyaluronic acid (HA) increase expression 
of IL-1β, IL-6, IL-8, MMP-1, and MMP-13 by NP cells 
by binding to TLR2 (Quero et al., 2013). Additionally, 
excessive mechanical loading of IVD cells, a contributor to 
disc disease, has also been shown to upregulate TLR2 and 
TLR4 expression (Gawri et al., 2014). Thus, ECM proteins, 
particularly fragments generated during the degenerative 
process, binding to TLRs on NP cells can potentiate the 
Fig. 2. Schematic showing the major phases of intervertebral disc degeneration and discogenic back pain. Potential 
triggering events include overt trauma to the disc, altered loading, genetic predisposition and spinal infection. These 
triggers result in NP and AF cell-mediated synthesis of cytokines such as TNF-α, IL-1β, and IL-6. These cytokines 
have at least three major effects: increased matrix breakdown through production of SDC4, ADAMTS4/5 and MMPs, 
activation and chemotaxis of immune cells to the disc, and induction of neurotrophins (NGF, BDNF) by disc cells 
and immunocytes. NGF and BDNF induce production of pain-associated channels ASIC3 and Trpv1 in the DRG. 
Presence of these factors in the inflammatory microenvironment of the degenerated disc is thought to promote DRG 
sensitisation and pain. Blocking of cytokine production in Phases 1 and 2 may have the most profound positive 
effect on disease progression and back pain. Red blocking symbols indicate possible areas for clinical intervention. 
Abbreviations: ADAMTS4/5, a disintegrin and metalloproteinase with thrombospondin motifs 4/5; ASIC3, acid-sensing 
ion channel 3; BDNF, brain-derived neurotrophic factor; β-NGF, β-nerve growth factor; DRG, dorsal root ganglion; 
IFN-γ, interferon-γ; MMPs, matrix metalloproteinases; SDC4, syndecan-4; TrpV1, transient receptor potential cation 
channel subfamily V member 1. (Adapted from Risbud and Shapiro, 2014)
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pathogenesis of disc degeneration (See schematic in Fig. 2 
for various phases of disc degeneration and possible areas 
for intervention, as indicated by red blocking symbols).
Immune cells are activated by disc cells in response 
to TNF and IL-1
In addition to affecting matrix homeostasis, cytokines 
also induce NP cells to synthesise many cytokines and 
chemokines that can further enhance the inflammatory state 
by recruiting and activating immune cells. Gruber et al. 
(2013) showed that production of IL-17 is correlated with 
severity of degeneration and was induced by TNF-α and 
IL-1β. Human IVD cells, in response to IL-1β treatment, 
increase production of COX-2 and IL-6 as well as IL-1β 
itself, creating a positive feedback loop (Jimbo et al., 2005). 
When exposed to TNF-α, human IVD cells increased 
production of the tachykinin peptide Substance P, which 
subsequently induced expression of IL-1β, IL-6 and IL-8, 
a chemoattractant for neutrophils (Kepler et al., 2012). 
Similarly, IVD cells, following treatment with TNF-α 
and IL-1β, produce CCL5/RANTES, a chemoattractant 
for macrophages and eosinophils, and the expression 
is correlated with both discogenic pain and severity of 
degeneration (Kepler et al., 2013; Gruber et al., 2014a). 
When treated with IL-1β or TNF-α, both NP and AF cells 
produced monocyte chemoattractant protein-1 (MCP-1/
CCL2) in a dose- and time-dependent manner. This was 
also demonstrated in a surgically-induced rabbit IVD 
herniation model (Yoshida et al., 2002; Yoshida et al., 
2005). Human AF cells also induced expression of MCP-1/
CCL2 in response to IL-1β treatment (Gruber et al., 2015). 
Other macrophage chemoattractants, such as CCL3/MIP-
1α and CCL4/MIP-1β, are expressed by NP cells, and their 
expression is regulated by TNF-α or IL-1β through MAPK 
and NF-κB pathways. Interestingly, while p65 induces the 
expression of CCL3, p50 showed inhibitory effects on 
CCL3 expression. Importantly, expression of CCL3 has 
been correlated to severity of degeneration in human NP 
tissue (Wang et al., 2013b).
 It is worth noting that IVD cells themselves express 
chemokine receptors, although their physiologic function 
and precise role in degeneration is not yet fully elucidated. 
IVD cells express CCL5 receptors CCR1, CCR3 and 
CCR5 (Gruber et al., 2014a). In a recent report, Phillips 
et al. (2015) showed expression of CCR1, CXCR1 and 
CXCR2 by human NP cells in situ; expression of CXCR2 
significantly correlated with the grade of degeneration. 
Surprisingly, NP cells were also positive for CD4, a 
receptor exclusively expressed by immune cells, more 
prominently by the CD4+ T helper cells, an observation 
that requires further careful investigation. Even though 
human NP cells expressed these chemokine receptors, 
treatment of primary human NP cells with IL-16, CCL2, 
CCL3, CCL7 or CXCL8 did not induce inflammatory 
responses or ECM remodelling. Rather, IL-1β treatment 
was able to induce cytokines and chemokines as well as 
ECM remodelling, suggesting IL-1β as a key player in 
modulating inflammatory process in intervertebral disc 
(Phillips et al., 2015).
TNF and IL-1 affect homeostatic activities of IVD 
cells
In addition to the effects on the matrix, inflammatory 
cytokines can also directly affect disc cell survival and 
functionality. A study from Purmessur et al. (2013) showed 
in a bovine organ culture model that TNF-α induced cell 
senescence along with anti-anabolic and pro-catabolic 
activities of the resident cells. In a rat organ culture model 
of disc degeneration, tissues were cultured with TNF-α, IL-
1β and serum limiting conditions, and showed differential 
expression of many genes involved in cell cycle, cell 
death, cellular growth and proliferation (Ponnappan et 
al., 2011). In addition, human AF cells exposed to both 
IL-1β and TNF-α significantly downregulated growth 
differentiation factor 5 (GDF5) (Gruber et al., 2014b), 
which has previously been demonstrated to be an important 
anabolic factor in disc (Li et al., 2004). Microarray analysis 
of human outer and inner AF tissue revealed higher GDF5 
expression in herniated lumbar discs, compared to non-
herniated lumbar discs (Gruber et al., 2014b). Another 
central mediator critical to disc cell proliferation is the 
Notch signalling pathway (Hiyama et al., 2011). TNF-α 
and IL-1β treatment of NP cells increased expression of 
NOTCH1 and NOTCH2 receptors along with their ligand 
Jagged-2, and downstream transcription factors HES1, 
HEY1 and HEY2. In addition, levels of NOTCH2 were 
increased in degenerative human NP tissues compared to 
non-degenerative samples, suggesting cytokine-mediated 
aberration in Notch signalling may affect cellular 
proliferation and differentiation in disc degeneration (Wang 
et al., 2013a).
 There is emerging evidence that even transient exposure 
to cytokines may have lasting effects on the IVD. In 
a 2014 study, Maidhof et al. (2014) demonstrated that 
inflammatory stimuli have a permanent effect on IVD cell 
biophysical properties. After 24 h of treatment with TNF-α, 
hydraulic permeability and cell radius of NP cells were 
altered for 1 week. These authors also noted a decrease 
in the expression of water channel Aquaporin 1, which 
has been recently shown to be associated with severity of 
degenerative disc disease (Maidhof et al., 2014; Johnson et 
al., 2015). Similarly, in a bovine disc organ culture model, 
short-term TNF-α treatment has been shown to result in 
long-term catabolic effects without negatively affecting 
cell viability (Purmessur et al., 2013). Likewise, human 
AF cells treated with IL-1β displayed greater and sustained 
increase in intracellular calcium concentration in response 
to laminar fluid flow, indicating IL-1β “sensitises” the AF 
to mechanical loading and sheer stress (Elfervig et al., 
2001).
TNF and IL-1 may play a critical role in resolution of 
disc herniation
While the high cytokines levels associated with chronic 
inflammation negatively affect the ECM and cell viability 
during disc degeneration, it is also important to note that 
TNF-α and IL-1β (Genevay et al., 2009) play an important 
role in natural resolution of disc herniation. It is well known 
that the majority of patients with disc herniation do not 
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develop symptoms of chronic LBP and radiculopathy due 
to neutrophil and macrophage-mediated timely resorption 
of the extruded NP tissue (Iwabuchi et al., 2008). One study 
has shown that TNF-α was required to induce MMP-3 in 
the herniated tissue, which acted as a chemoattractant for 
macrophages necessary for resorption (Haro et al., 2000). 
Immunoreactivity to TNF-α in the dorsal root ganglion 
(DRG) was increased following exposure to NP material 
in a rat model of disc herniation (Murata et al., 2004). 
Application of TNF-α inhibitor during surgery abrogated 
macrophage infiltration and VCAM-1 expression in the 
DRG. These results suggest that TNF-α plays a critical role 
in the coordination of macrophage infiltration following 
herniation of NP tissue (You et al., 2013). Likewise, 
inhibition of IL-1 by IL-1ra resulted in decreased active 
MMP-3 in human disc herniation samples, suggesting a 
contribution of IL-1 to this process (Genevay et al., 2009).
 While these results demonstrate the importance 
of TNF-α and IL-1 in resolution of disc herniation, as 
discussed above, an unchecked inflammatory response is 
likely deleterious to the disc. It is therefore desirable to 
devise a strategy to carefully control timing and magnitude 
of the inflammatory response by using agents such as 
sTNFRII (Sinclair et al., 2011), IL-1ra (Le Maitre et al., 
2006; Shamji et al., 2007; Gorth et al., 2012), and anti-
chemotactic agents (Wang et al., 2013b).
New therapies and future directions for the treatment 
of disc disease
Several approaches have been studied to counteract the 
effects of TNF-α on disc degeneration. BMP-7 is able 
to counteract TNF-α-induced activation of NF-κB and 
subsequent induction of ADAMTS4 and ADAMTS5, 
thereby preventing TNF-induced matrix loss in human 
disc cells (Wang et al., 2014b). Platelet rich plasma, or 
PRP, has also been shown to reduce the TNF- and IL-1-
mediated decreases in collagen II and aggrecan expression 
levels in human NP cells (Kim et al., 2014). Finally, LIM 
mineralisation protein-1 (LMP-1) has recently been shown 
to prevent TNF-α-mediated induction of MMP-3 and -13 
in rat NP cells (Liu et al., 2015).
 A recent study by Walter et al. (2015b) demonstrated 
that production of IL-1β, IL-6 and IL-8 by diseased human 
NP cells in response to TNF-α was at vastly different rates 
and magnitudes, suggesting different roles these cytokines 
may play in disc disease. Unlike reported by previous 
studies, blocking IL-6 or IL-1β did not affect the expression 
of other pro-inflammatory cytokines in response to TNF-α 
treatment. Anti-TNF-α therapy, given at the same time 
as TNF-α stimulation, was most effective at inhibiting 
expression of these cytokines (Walter et al., 2015b).
 Other studies have suggested a possible role for anti-
IL-1β therapy as a treatment modality. Co-treatment of 
agarose-encapsulated bovine NP cells with both IL-1β 
and IL-1ra abolished the catabolic effect caused by IL-
1β (Smith et al., 2011). When IL-1ra was introduced 
to degenerate human IVD explants, matrix degradation 
as well as expression of MMPs and ADAMTSs were 
successfully blocked (Le Maitre et al., 2007a). Similarly, 
medium conditioned with IL-1ra encapsulated in PLGA 
microspheres was effective in attenuating the effect of IL-
1β on bovine NP cells (Gorth et al., 2012). Shamji et al. 
(2007) used recombinant human elastin-like polypeptide 
(ELP)-IL-1ra fusion protein to promote prolonged release 
of IL-1ra, and were successful in decreasing TNF-α 
expression and ADAMTS4 and MMP-3 transcription in 
human IVD cells. In addition, Krupkova et al. (2014) 
demonstrated that degenerate human IVD cells treated in 
vitro with epigallocatechin 3-gallate (EPCG) significantly 
inhibited the expression of pro-inflammatory cytokines and 
MMPs in response to IL-1β treatment, and also showed in 
vivo reduction of radiculopathic pain in rats treated with 
EPCG.
 A study by Gu et al. (2015) showed miR-146a has a 
protective effect on IL-1-induced IVD degeneration. When 
bovine NP cells transfected with a miR-146a mimic were 
treated with IL-1, induction of inflammatory cytokines 
and matrix protease gene expression was decreased. 
Additionally, IVDs from miR-146a-/- mice ex vivo showed 
greater degradation of proteoglycan and increased 
level of MMP-13 and ADAMTS-5 after treatment with 
IL-1, suggesting a new potential therapeutic approach 
in modulating IL-1 activity in disc disease (Gu et al., 
2015). Importantly, in addition to these laboratory-based 
investigations, few clinical studies have tested efficacy of 
anti-TNF-α and anti-IL-1β therapies for treatment of back 
and radicular pain (see Table 1 for details). These clinical 
studies suggest that anti-cytokine therapies as well as, in 
a subset of patients, antibiotic regimens hold promise in 
treating low back and radicular pain.
 Current treatment modalities for disc degeneration 
and LBP are limited and lack efficacy (Martin et al., 
2008; Williams et al., 2014). Therefore, these new, 
targeted therapeutic strategies hold much promise. Careful 
consideration must be taken, however, when using anti-
cytokine treatment. As mentioned above, TNF-α and 
IL-1β play necessary positive roles in natural resolution 
of NP herniation. Additionally, also mentioned above, 
even transient exposure to LPS or TNF-α results in 
lasting biophysical changes in NP cells (Maidhof et al., 
2014). In light of this evidence, the timing of targeted 
anti-inflammatory treatment modalities is likely to have a 
critical impact on overall efficacy and success of therapy. 
Although a definitive “cure” for disc degeneration is 
far in the future, current research is providing hope for 
researchers and clinicians for improving patient outcomes 
for degenerative disc disease and LBP.
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Discussion with Reviewers
Reviewer I: In the concluding paragraph the importance 
of the appropriate timing of anti-inflammatory treatment 
is highlighted. In view of the phases described in Fig. 2, at 
which stage(s) would anti-inflammatory therapy be most 
appropriate?
Authors: Because of the chronic and progressive nature 
of disc disease, anti-inflammatory treatments are best 
started earlier in the disease process. We are therefore of 
the opinion that Phases I and II would be most appropriate 
for anti-inflammatory therapy. The caveat, however, is 
that often times the disease is not clinically manifested 
until much later in its course, which likely would limit the 
maximal benefits of such treatments.
Reviewer II: The study by Albert et al. (2013b) has raised 
major interest amongst clinicians. How much relevance do 
the authors assign to bacterial infection during degenerative 
disc disease and which approach would they apply to 
further investigate this aspect?
Authors: The nucleus pulposus is an avascular and 
confined tissue, making bacterial colonisation difficult 
when the continuity of the tissue is maintained, thus 
making primary infection of the nucleus pulposus an 
unlikely initiating cause of disc disease. The Albert study 
does suggest, however, that bacterial infection in a certain 
subset of patients can at least promote symptomatic disc 
disease and chronic LBP. It is important to note that all 
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of the patients in the Albert study had previous nuclear 
herniations, where extruded NP material would be exposed 
to vasculature and surrounding connective tissue, and 
Type I Modic changes. It would therefore be interesting 
to explore whether a correlation exists between persistent 
and refractory LBP following herniation, and increased 
likelihood of bacteraemia (e.g. prolonged catheter use, 
recent oral surgery, history of infective endocarditis, 
etc.), when disc material could potentially be colonised. 
One could then investigate whether bacterial infection 
post-herniation alters hernia resolution and/or promotes 
persistent inflammatory and nociceptive cascades with 
involvement of immune cells. A more comprehensive 
study that does not exclude chronic LBP patients without 
Modic changes would further provide understanding of the 
potential contribution of bacterial infection to progression 
of disc disease in the general population.
Editor’s Note: Scientific Editor in charge of the paper: 
Stephen Ferguson.
